Figure 5.
Pharmacokinetic-pharmacodynamic (PK-PD) simulation showing the relative contribution of S-ketmaine and S-norketamine to measured effect. A and C. Simulated pharmacokinetic (A) and pharmacodynamic data (C) assuming placebo pretreatment. B and D. Simulated pharmacokinetic (B) and pharmacodynamic data (D) assuming rifampicin pretreatment. VAS = visual analogue score.